Enhanced immune response of red deer (Cervus elaphus) to live rb51 vaccine strain using composite microspheres

Journal of Wildlife Diseases

Volumn 45, Issue 1, 2009, Pages 165-173

  Arenas Gamboa, Angela M ^a,b   Ficht, Thomas A ^a   Davis, Donald S ^a   Elzer, Philip H ^c   Wong Gonzalez, Alfredo ^a   Rice Ficht, Allison C ^b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c LOUISIANA STATE UNIVERSITY AGRICULTURAL CENTER   (United States)

Author keywords

Brucella; Elk; Microencapsulation; Vaccines; Vitelline protein b

Indexed keywords

ANIMALIA; BACTERIA (MICROORGANISMS); BISON; BISON BISON; BOS; BRUCELLA; BRUCELLA MELITENSIS BIOVAR ABORTUS; CERVUS; CERVUS ELAPHUS; FASCIOLA HEPATICA;

BACTERIUM ANTIBODY; BRUCELLA VACCINE; LIVE VACCINE; MICROSPHERE;

ANIMAL; ANIMAL DISEASE; ANTIBODY PRODUCTION; ARTICLE; BIOSYNTHESIS; BLOOD; BRUCELLA ABORTUS; BRUCELLOSIS; CELLULAR IMMUNITY; DEER; DISEASE CARRIER; FEMALE; IMMUNOLOGY; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PREVALENCE; RANDOMIZATION; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VACCINATION; VETERINARY ABORTION; WILD ANIMAL; ZOONOSIS;

ABORTION, VETERINARY; ADMINISTRATION, ORAL; ANIMALS; ANIMALS, WILD; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; BRUCELLA ABORTUS; BRUCELLA VACCINE; BRUCELLOSIS; DEER; DISEASE RESERVOIRS; FEMALE; IMMUNITY, CELLULAR; INJECTIONS, SUBCUTANEOUS; MICROSPHERES; PREVALENCE; RANDOM ALLOCATION; RISK FACTORS; TREATMENT OUTCOME; VACCINATION; VACCINES, ATTENUATED; ZOONOSES;

EID: 65249155325     PISSN: 00903558     EISSN: None     Source Type: Journal    
DOI: 10.7589/0090-3558-45.1.165     Document Type: Article

References (29)

1. ABRAHAM, S. M., R, F. VIETH, AND D. J. BURGESS. 1996. Novel technology for the preparation of sterile alginate-poly-L-lysine microcapsules in a bioreactor. Pharmaceutical Development and Technology 1: 63-68.
2. ASHFORD, D. A., J. DI PIETRA, J. LINGAPPA, C. WOODS, H. NOLL, B. NEVILLE, R. WEYANT, S. L. BRAGG, R. A. SPIEGEL, J. TAPPERO, AND B. A. PERKINS. 2004. Adverse events in humans associated with. accidental exposure to the livestock brucellosis vaccine RB51. Vaccine 22: 3435-3439.
3. BERKELMAN, R. L. 2003. Human illness associated with use of veterinary vaccines. Clinical Infectious Diseases 37: 407-414.
4. BOSCHIROLI, M. L., V. FOULONGNE, AND D. O'CALLAGHAN. 2001. Brucellosis: A worldwide zoonosis. Current Opinions in Microbiology 4: 58-64.
5. COOK, W. E., E. S. WILLIAMS, E. T. THORNE, T. J. KREEGER, G. STOUT, K. BARDSLEY, H. EDWARDS, G. SCHURIG, L. A. COLBY, F. ENRIGHT, AND P. H. ELZER. 2002. Brucella abortus strain RB51 vaccination in elk, I: Efficacy of reduced dosage. Journal of Wildlife Diseases 38: 18-26. (Pubitemid 135692463)
6. CORBEL, M. J. 1997. Brucellosis: An overview. Emerging Infectious Diseases 3: 213-221.
7. DAVIS, D. S., AND P. H. ELZER. 2002. Brucella vaccines in wildlife. Veterinary Microbiology 90: 533-544.
8. -, J. W. TEMPLETON, T. A. FICHT, J. D. HUBER, R. D. ANGUS, AND L. G. ADAMS. 1991. Brucella abortus in Bison, II: Evaluation of strain 19 vaccination, of pregnant cows. Journal of Wildlife Diseases 27: 258-264.
9. ELZER, P. H., J. SMITH, T. ROFFE, T. KREEGER, J. EDWARDS, AND D. DAVIS. 2002. Evaluation of Brucella abortus strain RB51 and strain 19 in pronghorn antelope. Annals of the New York Academy of Science 969: 102-105.
10. ETTER, R. P., AND M. L. DREW. 2006. Brucellosis in elk of eastern Idaho. Journal of Wildlife Diseases 42: 271-278.
11. EYLES, J. E., V. W. BRAMWELL, E. D. WILLIAMSON, AND H. O. ALFAR. 2001. Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration. Vaccine 19: 4732-4742.
12. JANUSZEWSKI, M. C., S. C. OLSEN, R. G. MCLEAN, L. CLARK, AND J. C. RHYAN. 2001. Experimental infection of nontarget species of rodents and birds with Brucella abortus strain. RB51 vaccine. Journal, of Wildlife Diseases 37: 532-537.
13. KAHL-MCDONAGH, M. M., AND T. A. FICHT. 2006. Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice. Infection and Immunity 74: 4048-4057.
14. KREEGER, T. J., M. W. MILLER, M. A. WILD, P. H. ELZER, AND S. C. OLSEN. 2000. Safety and efficacy of Brucella abortus strain RB51 vaccine in captive pregnant elk. Journal of Wildlife Diseases 36: 477-483.
15. -, W. E. COOK, W. H. EDWARDS, P. H. ELZER, AND S. C. OLSEN. 2002a. Brucella abortus strain RB51 vaccination in elk. II. Failure of high dosage to prevent abortion. Journal of Wildlife Diseases 38: 27-31.
16. -, T. J. DELIBERTO, S. C. OLSEN, W. H. EDWARDS, AND W. E. COOK. 2002b. Safety of Brucella abortus strain RB51 vaccine in nontarget ungulates and coyotes. Journal of Wildlife Diseases 38: 552-557.
17. LIMA, K. M., AND J. M. RODRIGUES, JR. 1999. Poly-DL-lactide-co-glyeolide microspheres as a controlled release antigen, delivery system. Brazilian Journal of Medical and Biological research. 32: 171 180.
18. OLSEN, S. C., T. J. KREEGER, AND M. V. PALMER. 2002. Immune responses of elk to vaccination with Brucella abortus strain RB51. Journal of Wildlife Diseases 38: 746-751.
19. -, J. RHYAN, T. GIDLEWSKI, J. GOFF, AND W. C. STOFFREGEN. 2004. Safety of Brucella abortus strain. RB51 in black bears. Journal of Wildlife Diseases 40: 429-433.
20. PASTORET, P. P., AND B. BROCHIER. 1996. The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies: A link between Jenner and Pasteur. Epidemiology and Infection 116: 235-240.
21. RAGAN, V. E. 2002. The Animal and Plant Health Inspection Service (APHIS) brucellosis eradication program in the United States. Veterinary Microbiology 90: 11-18.
22. RICE-FICHT, A. C., K. A. DUSEK, G. J. KOCHEVAR, AND J. H. WATTE. 1992. Eggshell precursor proteins of Fasciola hepatica, I. Structure and expression of vitelline protein B. Molecular and Biochemical Parasitology 54: 129-141.
23. SCHNEIDER, L. G. 1995. Rabies virus vaccines. Developments in Biological Standardization 84: 49-54.
24. SCHUHIG, G. G., N. SRIRANGANATHAN, AND M. J. CORBEL. 2002. Brucellosis vaccines: Past, present and future. Veterinary Microbiology 90: 479-496. (Pubitemid 35282500)
25. SUN, H., K. G. POLLOCK, AND J. M. BREWER. 2003. Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine 21: 849-855.
26. THORNE, E. T., J. MORTON, AND W. RAY. 1980. Brucellosis, its effect and impact on elk in western Wyoming. University of Wyoming Press, Laramie, Wyoming.
27. WATERS, W. R., R. E. SACCO, S. J. FACH, M. V. PALMER, S. C. OLSEN, AND T. J. KREEGER. 2002. Analysis of mitogen-stimulated lymphocyte subset proliferation and nitric oxide production by peripheral blood mononuclear cells of captive elk (Cervus elaphus). Journal of Wildlife diseases 38: 344-351.
28. WEE, S., AND W. R. GOMBOTZ. 1998. Protein release from alginate matrices. Advanced Drug Delivery Reviews 31: 267-285.
29. ZHAN, Y., A. KELSO, AND C. CHEERS. 1995. Differential activation of Brucella-reactive CD4+ T cells by Brucella infection or immunization with antigenic extracts. Infection and Immunity 63: 969-975.